Application of 129-18-0. So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide, is researched, Molecular C19H19N2NaO2, CAS is 129-18-0, about Objective and timing of drug disposition studies. IV. Phenylbutazone formulations. In vitro dissolution and in vivo performance.
GP 26872 [129-18-0] (a glycerin solution of phenylbutazone Na salt) produced a more rapid onset of plasma levels of phenylbutazone (I) [50-33-9] as well as higher maximum concentration than pure I but the amount of drug absorbed was not significantly different. The dissolution rate of capsules was in the following decreasing order: pure GP 26872 > pure I > formulated I > formulated GP 26872. A film coated I tablet gave an average plasma level of ∼15 μg/ml in 30 min, whereas with a sugar coated tablet these peak levels were not attained until 3 hr. Peak levels were 34 and 57 μg/ml with the film coated tablet and 19 and 32 μg/ml with the sugar coated tablet. I was pure I in capsules.
This literature about this compound(129-18-0)Application of 129-18-0has given us a lot of inspiration, and I hope that the research on this compound(Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide) can be further advanced. Maybe we can get more compounds in a similar way.
Reference:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem